Federal Register / Vol. 71, No. 179 / Friday, September 15, 2006 / Notices 54505 

with a chemokine receptor ligand, 

chemokines and other chemoattractants 

that enables specific targeting and 

delivery to the Treg cells. This 

technology is advantageous over the 

more harmful antibodies and chemicals 

that are currently used for the systemic 

depletion of Treg cells. The current 

technology can be used therapeutically 

in a variety of ways. They can be used 

together with vaccines to increase 

efficacy of the vaccine for the treatment 

of cancer, and can used to locally 

deplete Treg cells or other immuno 

suppressive cells to induce cytolytic cell 

responses at the tumor site or to 

eliminate chronic infectious diseases 

such as HIV and tuberculosis. 

Applications: 

1. New chemoattractant based toxins 

targeted towards Treg cells. 

2. New chemoattractant based toxins 

targeted towards immunosuppressive 

NKT, and macrophages. 

3. New chemoattractant based toxins 

targeted towards local depletion of 

hyperactivated CD4 T cells to treat 

autoimmune diseases. 

4. Chemoattractant based toxins 

depleting Treg cells or other 

immunosuppressive cells causing 

enhanced vaccine immune responses. 

5. Novel immunotherapy by 

increasing vaccine efficacy against 

cancer and infectious diseases. 

Market: 

1. 600,000 deaths from cancer related 

diseases estimated in 2006. 

2. The technology platform involving 

novel chemo-attractant based toxins can 

be used to improve vaccine immune 

responses. The vaccine market is 

believed to reach $10bn in 2006. 

3. The technology platform has 

additional market in treating several 

other clinical problems such as 

autoimmune diseases. 

Development Status: The technology 

is currently in the pre-clinical stage of 

development. 

Inventors: Arya Biragyn (NIA), Dolgor 

Bataar (NIA), et al. (Lead Inventor Web 

page: http://www.grc.nia.nih.gov/ 

branches/irp/abiragyn.htm). 

Related Publications: 

1. Copy of manuscript from this 

technology can be provided once 

accepted for publication. 

2. M Coscia, A Biragyn. Cancer 

immunotherapy with chemoattractant 

peptides. Semin Cancer Biol 2004 Jun; 

14(3):209–218. 

3. R Schiavo et al. Chemokine 

receptor targeting efficiently directs 

antigens to MHC class I pathways and 

elicits antigen-specific CD8+ T-cell 

responses. Blood 2006 Jun 15; 107 

(12):4597–4605. Epub 2006 Mar 2, doi 

10.1182/blood–2005–08–3207. 

Patent Status: U.S. Provisional 

Application No. 60/722,675 filed 30 Sep 

2005, entitled ‘‘Methods and 

Compositions for Modulating Immune 

Tolerance’’ (HHS Reference No. E–027–

2005/0–US–01). 

Licensing Status: Available for nonexclusive or exclusive licensing. 

Licensing Contact: Thomas P. Clouse, 

J.D.; 301/435–4076; 

clousetp@mail.nih.gov. 

Collaborative Research Opportunity: 

The NIA Laboratory of Immunology is 

seeking statements of capability or 

interest from parties interested in 

collaborative research to further 

develop, evaluate, or commercialize 

novel chemoattractant-based toxins. 

Please contact Betty Tong at 301–496–

0477 or tongb@mail.nih.gov for more 

information. 

Dated: September 8, 2006. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E6–15294 Filed 9–14–06; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center for Research 

Resources; Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Center for 

Research Resources Initial Review Group; 

Clinical Research Review Committee. 

Date: October 4–5, 2006. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Residence Inn Bethesda, 7335 

Wisconsin Avenue, Bethesda, MD 20814. 

Contact Person: Mohan Viswanathan, PhD, 

Deputy Director, National Center for 

Research Resources, OR, National Institutes 

of Health, 6701 Democracy Blvd., Room 

1084, MSC 4874, 1 Democracy Plaza, 

Bethesda, MD 20892–4874; 301–435–0829; 

mv10f@nih.gov. 

Name of Committee: National Center for 

Research Resources Special Emphasis Panel; 

CMRC–A 

Date: October 5, 2006. 

Time: 9 a.m. to 10 a.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, One 

Democracy Plaza, 6701 Democracy 

Boulevard, Bethesda, MD 20892. (Telephone 

Conference Call). 

Contact Person: John R. Glowa, PhD, 

Scientific Review Administrator, Office of 

Review, National Center for Research 

Resources, 6701 Democracy Boulevard, Room 

1078—MSC 4874, Bethesda, MD 20892–4874; 

301.435.0807; glowaj@mail.nih.gov. 

Name of Committee: National Center for 

Research Resources Initial Review Group; 

Comparative Medicine Review Committee. 

Date: October 10–11, 2006. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Double Tree Rockville, 1750 

Rockville Pike, Roosevelt Room, Rockville, 

MD 20852. 

Contact Person: John R. Glowa, PhD, 

Scientific Review Administrator, Office of 

Review, National Center for Research 

Resources, 6701 Democracy Boulevard, Room 

1078—MSC 4874; Bethesda, MD 20892–4874; 

301.435.0807; glowaj@mail.nih.gov. 

Name of Committee: National Center for 

Research Resources Special Emphasis Panel; 

GCRC and K23 SEP. 

Date: October 19–20, 2006. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Gaithersburg Hilton, 620 Perry 

Parkway, Gaithersburg, MD 20877. 

Contact Person: Guo Zhang, PhD, Scientific 

Review Administrator, National Center for 

Research Resources/OR, National Institutes 

of Health, 6701 Democracy Boulevard, 1 

Democracy Plaza, Rm. 1064, Bethesda, MD 

20892–4874; 301–435–0812; 

zhanggu@mail.nih.gov. 

Name of Committee: National Center for 

Research Resources Special Emphasis Panel; 

RCMI Net Teleconference. 

Date: October 26, 2006. 

Time: 1 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, One 

Democracy Plaza, 6701 Democracy 

Boulevard, Bethesda, MD 20892; (Telephone 

Conference Call). 

Contact Person: Guo Zhang, PhD, Scientific 

Review Administrator, Office of Review, 

National Center for Research Resources, 

National Institutes of Health, 6701 

Democracy Boulevard, 1 Democracy Plaza, 

Rm. 1064, Bethesda, MD 20892; (301) 435–

0812; zhanggu@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research; 93.371, Biomedical 

Technology; 93.389, Research Infrastructures, 

93.306, 93.333, National Institutes of Health, 

HHS) 


jlentini on PROD1PC65 with NOTICES
54506 Federal Register / Vol. 71, No. 179 / Friday, September 15, 2006 / Notices 

Dated: September 8, 2006. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 06–7666 Filed 9–14–06; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commerical 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committe: National Heart, Lung, 

and Blood Institute Special Emphasis Panel, 

Research Program Project in Hypertension 

Management. 

Date: October 4, 2006. 

Time: 8 a.m. to 12 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hilton Garden Inn Washington DC 

Franklin Square, 815 14th Street, NW., 

Washington, DC 20005. 

Contact Person: Holly Patton, PhD, 

Scientific Review Administrator, Review 

Branch/Division of Extramural Affairs, 

National Heart, Lung, and Blood Institute, 

Two Rockledge Center, 7188, 6701 Rockledge 

Dr, Bethesda, MD 20892, 301–435–0280. 

pattonh@nhlbi.nih.gov. 

Name of Committe: National Heart, Lung, 

and Blood Institute Special Emphasis Panel, 

Midcareer Investigator Award in PatientOriented Research—K24. 

Date: November 2, 2006. 

Time: 12 p.m. to 1 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Courtyard Arlington Crystal City/ 

Reagon National, 2899 Jefferson Davis Hwy., 

Arlington, VA 22202. 

Contact Person: Mark Roltsch, PhD, 

Scientific Review Administrator, Review 

Branch, NHLBI, National Institutes of Health, 

6701 Rockledge Drive, Room 7192, Bethesda, 

MD 20892, 301–435–0287. 

roltschm@mail.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: September 8, 2006. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 06–7669 Filed 9–14–06; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Initial Review Group; Digestive Diseases and 

Nutrition C Subcommittee. 

Date: October 12–13, 2006. 

Open: October 12, 2006, 8 a.m. to 8:30 a.m. 

Agenda: To review procedures and discuss 

policy. 

Place: Double Tree Rockville, 1750 

Rockville Pike, Rockville, MD 20852. 

Closed: October 12, 2006, 8:30 a.m. to 5 

p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Double Tree Rockville, 1750 

Rockville Pike, Rockville, MD 20852. 

Closed: October 13, 2006, 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Double Tree Rockville, 1750 

Rockville Pike, Rockville, MD 20852. 

Contact Person: Paul A. Rushing, PhD, 

Scientific Review Administrator, Review 

Branch, DEA, NIDDK, National Institutes of 

Health, Room 747, 6707 Democracy 

Boulevard, Bethesda, MD 20892–5452; (301) 

594–8895; rushingp@extra.niddk.nih.gov. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Initial Review Group; Kidney, Urologic and 

Hematologic Diseases D Subcommittee. 

Date: October 18–19, 2006. 

Open: October 18, 2006, 2 p.m. to 2:30 p.m. 

Agenda: To review procedures and discuss 

policy. 

Place: Crystal City Courtyard by Marriott, 

2899 Jefferson Davis Highway, Crystal City, 

VA 22202. 

Closed: October 18, 2006, 2:30 p.m. to 4 

p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Crystal City Courtyard by Marriott, 

2899 Jefferson Davis Highway, Crystal City, 

VA 22202. 

Closed: October 19, 2006, 8 a.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Crystal City Courtyard by Marriott, 

2899 Jefferson Davis Highway, Crystal City, 

VA 22202. 

Contact Person: Neal A. Musto, PhD, 

Scientific Review Administrator, Review 

Branch, DEA, NIDDK, National Institutes of 

Health, Room 751, 6707 Democracy 

Boulevard, Bethesda, MD 20892–5452; (301) 

594–7798; muston@extra.niddk.nih.gov. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Initial Review Group; Diabetes, 

Endocrinology and Metabolic Diseases B 

Subcommittee. 

Date: October 25–26, 2006. 

Open: October 25, 2006, 6:30 p.m. to 7 p.m. 

Agenda: To review procedures and discuss 

policy. 

Place: Bethesda Park Hotel, 8400 

Wisconsin Avenue, Bethesda, MD 20814. 

Closed: October 25, 2006, 7 p.m. to 9:30 

p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda Park Hotel, 8400 

Wisconsin Avenue, Bethesda, MD 20814. 

Closed: October 26, 2006, 8 a.m. to 4:30 

p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda Park Hotel, 8400 

Wisconsin Avenue, Bethesda, MD 20814. 

Contact Person: John F. Connaughton, PhD, 

Scientific Review Administrator, Review 

Branch, DEA, NIDDK, National Institutes of 

Health, Room 916, 6707 Democracy 

Boulevard, Bethesda, MD 20892–5452; (301) 

594–7797; 

connaughtonj@extra.niddk.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 


jlentini on PROD1PC65 with NOTICES